Atea Pharmaceuticals, Inc.
AVIR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $2 | $3 | $0 |
| Gross Profit | $0 | -$2 | -$3 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $38 | $32 | $30 | $26 |
| G&A Expenses | $7 | $9 | $9 | $0 |
| SG&A Expenses | $7 | $9 | $9 | $13 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$2 | -$3 | $0 |
| Operating Expenses | $46 | $39 | $36 | $39 |
| Operating Income | -$46 | -$41 | -$39 | -$39 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4 | $4 | $5 | $6 |
| Pre-Tax Income | -$42 | -$37 | -$34 | -$33 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$42 | -$37 | -$34 | -$34 |
| % Margin | – | – | – | – |
| EPS | -0.53 | -0.44 | -0.4 | -0.4 |
| % Growth | -20.5% | -10% | 0% | – |
| EPS Diluted | -0.53 | -0.44 | -0.4 | -0.4 |
| Weighted Avg Shares Out | 79 | 84 | 85 | 84 |
| Weighted Avg Shares Out Dil | 79 | 84 | 85 | 84 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $4 | $5 | $6 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$42 | -$41 | -$39 | -$33 |
| % Margin | – | – | – | – |